| FDA供企业用药物升压效应评估指导原则的介绍 |
| |
| 引用本文： | 孙昱,萧惠来. FDA供企业用药物升压效应评估指导原则的介绍[J]. 现代药物与临床, 2018, 41(10): 1749-1752 |
| |
| 作者姓名： | 孙昱 萧惠来 |
| |
| 作者单位： | 国家药品监督管理局 药品审评中心, 北京 100022,国家药品监督管理局 药品审评中心, 北京 100022 |
| |
| 摘 要： | 药品如果产生长期的升压作用，可使使用者的心血管风险增加。在开发过程中系统地描述药物对血压的影响，逐渐引起监管部门的重视。美国食品药品管理局（FDA）于2018年5月发布了“供企业用药物升压效应评估指导原则”，旨在解决药品开发期间评估效应时血压测量的准确性。详细介绍该指导原则主要内容，期望对我国的新药研发和药品监管有所帮助。
|
| 关 键 词： | 美国食品药品管理局 药物升压效应 血压监测 新药研发 药品监管 |
| 收稿时间： | 2018-07-10 |
Introductions for assessment of pressor effects of drugs guidance for industry by FDA |
| |
| SUN Yu and XIAO Huilai. Introductions for assessment of pressor effects of drugs guidance for industry by FDA[J]. Drugs & Clinic, 2018, 41(10): 1749-1752 |
| |
| Authors: | SUN Yu and XIAO Huilai |
| |
| Affiliation: | Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China and Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China |
| |
| Abstract: | If the drug produces a long-term boost, it increases the cardiovascular risk of the user. In the process of development, the effects of drugs on blood pressure were systematically described, which gradually attracted the attention of regulators. In May 2018, FDA announced Assessment of Pressor Effects of Drugs Guidance for Industry, aiming to address the accuracy of blood pressure measurement when evaluating the effect during drug development. The main content of this guideline is introduced in detail, which is expected to be helpful for the development of new drugs and drug regulation in China. |
| |
| Keywords: | FDA pressor effects of drugs blood pressure measurement new drug research and development drug administration |
|
| 点击此处可从《现代药物与临床》浏览原始摘要信息 |
|
点击此处可从《现代药物与临床》下载全文 |
|
